Clinical trial NCT02342392 - References

Pterygium — Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Citation(s)

•   Ang LP, Chua JL, Tan DT
  Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007 Jul;18(4):308-13. Review.
•   Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A
  Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008 Jan;33(1):23-8. doi: 10.1080/02713680701799101.
•   Bayar SA, Kucukerdonmez C, Oner O, Akova YA
  Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol. 2014 Jun;34(3):541-7. doi: 10.1007/s10792-013-9852-1. Epub 2013 Sep 12.
•   Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY
  Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study. Cornea. 2012 Aug;31(8):937-44. doi: 10.1097/ICO.0b013e31823f8d71.
•   Besharati MR, Manaviat MR, Souzani A
  Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran. 2011;49(3):179-83.
•   Blaudschun R, Sunderkötter C, Brenneisen P, Hinrichs R, Peters T, Schneider L, Razi-Wolf Z, Hunzelmann N, Scharffetter-Kochanek K
  Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo. Br J Dermatol. 2002 Apr;146(4):581-7.
•   Di Girolamo N, Chui J, Coroneo MT, Wakefield D
  Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004 Mar;23(2):195-228. Review.
•   Enkvetchakul O, Thanathanee O, Rangsin R, Lekhanont K, Suwan-Apichon O
  A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea. 2011 Nov;30(11):1213-8. doi: 10.1097/ICO.0b013e31821c9b44.
•   Fallah Tafti MR, Khosravifard K, Mohammadpour M, Hashemian MN, Kiarudi MY
  Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea. 2011 Feb;30(2):127-9. doi: 10.1097/ICO.0b013e3181e16d67.
•   Galor A, Yoo SH, Piccoli FV, Schmitt AJ, Chang V, Perez VL
  Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. Am J Ophthalmol. 2010 Jun;149(6):926-931.e2. doi: 10.1016/j.ajo.2010.01.015. Epub 201
•   Hirst LW, Sebban A, Chant D
  Pterygium recurrence time. Ophthalmology. 1994 Apr;101(4):755-8.
•   Hosseini H, Nejabat M, Khalili MR
  Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69(4):925-7. Epub 2007 Mar 26.
•   Hu Q, Qiao Y, Nie X, Cheng X, Ma Y
  Bevacizumab in the treatment of pterygium: a meta-analysis. Cornea. 2014 Feb;33(2):154-60. doi: 10.1097/ICO.0000000000000037.
•   Hurmeric V, Vaddavalli P, Galor A, Perez VL, Roman JS, Yoo SH
  Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium. Clin Ophthalmol. 2013;7:467-73. doi: 10.2147/OPTH.S40400. Epub 2013 Mar 4.
•   Karalezli A, Kucukerdonmez C, Akova YA, Koktekir BE
  Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol. 2014 Jun 18;7(3):512-6. doi: 10.3980/j.issn.2222-3959.2014.03.23. eCol
•   Kocabora SM, Fazil K, Ozsutcu M, Doyduk-Kocabora A, Gulkilik G
  Subconjunctival bevacizumab injection in the surgery of primary pterygium: comparison with intraoperative mitomycin-C. Bull Soc Belge Ophtalmol. 2013;(322):7-12.
•   Lee DH, Cho HJ, Kim JT, Choi JS, Joo CK
  Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001 Oct;20(7):738-42.
•   Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P
  Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea. 2012 Feb;31(2):155-61. doi: 10.1097/ICO.0b013e3182151e0e
•   Mandalos A, Tsakpinis D, Karayannopoulou G, Tsinopoulos I, Karkavelas G, Chalvatzis N, Dimitrakos S
  The effect of subconjunctival ranibizumab on primary pterygium: a pilot study. Cornea. 2010 Dec;29(12):1373-9. doi: 10.1097/ICO.0b013e3181d927b9.
•   Mansour AM
  Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009 Jul;93(7):864-5. doi: 10.1136/bjo.2008.155291.
•   Nava-Castañeda A, Olvera-Morales O, Ramos-Castellon C, Garnica-Hayashi L, Garfias Y
  Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up. Clin Experiment Oph
•   Ozgurhan EB, Agca A, Kara N, Yuksel K, Demircan A, Demirok A
  Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea. 2013 Jun;32(6):835-8. doi: 10.1097/ICO.0b013e3182772d4e.
•   Poenaru Sava MG, Raica ML, Cimpean AM
  VEGF mRNA assessment in human pterygium: a new 'scope' for a future hope. Ophthalmic Res. 2014;52(3):130-5. doi: 10.1159/000363142. Epub 2014 Oct 3.
•   Prabhasawat P, Barton K, Burkett G, Tseng SC
  Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997 Jun;104(6):974-85.
•   Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T
  Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006 Jul;113(7):1102-9. Epub 2006 May 26.
•   Razeghinejad MR, Banifatemi M
  Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial. J Ophthalmic Vis Res. 2014 Jan;9(1):22-30.
•   Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H
  Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43(3):134-8. doi: 10.1159/000252980. Epub 2009 Oct 29.
•   Razeghinejad R, Banifatemi M, Hosseini H
  The effect of different doses of subconjunctival bevacizumab on the recurrence rate of excised primary pterygium. Bull Soc Belge Ophtalmol. 2013;(322):13-20.
•   Sarac O, Demirel S, Oltulu R
  Efficacy of intralesional bevacizumab administration in primary pterygium: a quantitative analysis. Eye Contact Lens. 2014 Jan;40(1):46-50. doi: 10.1097/ICL.0000000000000004.
•   Shahin MM, Elbendary AM, Elwan MM
  Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report. Ophthalmic Surg Lasers Imaging. 2012 Nov-Dec;43(6):459-66. doi: 10.3928/15428877-20120802-02. Epub 2012 Au
•   Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF
  Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011 Nov;30(11):1219-22. doi: 10.1097/ICO.0b013e31820ca63f.
•   Tan DT, Chee SP, Dear KB, Lim AS
  Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997 Oct;115(10):1235-40. Erratum in: Arch Ophthalmol 1998 Apr;116(4):552.
•   Tan DT, Lim AS, Goh HS, Smith DR
  Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol. 1997 Mar;123(3):404-5.
•   Teng CC, Patel NN, Jacobson L
  Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009 May;28(4):468-70. doi: 10.1097/ICO.0b013e31818d382d.
•   Wu PC, Kuo HK, Tai MH, Shin SJ
  Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea. 2009 Jan;28(1):103-4. doi: 10.1097/ICO.0b013e3181822615.

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Details for clinical trial NCT02342392